We are live on
!
Find out more
AA
AlphaCentric Advisors Portfolio holdings
AUM
$118M
This Fund
S&P 500
This Quarter
Est. Return
+3.46%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$343M
AUM Growth
-$50.3M
(-13%)
Cap. Flow
-$56.3M
Cap. Flow
% of AUM
-16.41%
Top 10 Holdings %
Top 10 Hldgs %
78.35%
Holding
286
New
92
Increased
41
Reduced
68
Closed
66
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares 1-3 Year Treasury Bond ETF
SHY
|
+$1.84M |
| 2 |
Jazz Pharmaceuticals
JAZZ
|
+$1.31M |
| 3 |
GXO Logistics
GXO
|
+$1.26M |
| 4 |
Aurora
AUR
|
+$1.11M |
| 5 |
Puma Biotechnology
PBYI
|
+$1.09M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard Mortgage-Backed Securities ETF
VMBS
|
+$30.4M |
| 2 |
iShares MBS ETF
MBB
|
+$29.8M |
| 3 |
Vertex Pharmaceuticals
VRTX
|
+$1.86M |
| 4 |
Azenta
AZTA
|
+$1.53M |
| 5 |
Synopsys
SNPS
|
+$1.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Real Estate | 24.12% |
| 2 | Healthcare | 12.62% |
| 3 | Financials | 1.65% |
| 4 | Technology | 1.41% |
| 5 | Industrials | 1.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Exelixis
EXEL
$13.9B
| $695K | 0.2% |
38,000
+15,000
| +65% | +$287K |
|
52
Enact Holdings
ACT
$6.53B
| $686K | 0.2% |
+33,168
| New | +$718K |
|
|
ADAM
53
Adamas Trust
ADAM
$777M
| $682K | 0.2% |
45,803
+6,250
| +16% | +$102K |
|
54
Celldex Therapeutics
CLDX
$2.77B
| $657K | 0.19% |
17,000
| – | – |
|
55
Welltower
WELL
$178B
| $643K | 0.19% |
7,500
+5,000
| +200% | +$417K |
|
56
iShares 7-10 Year Treasury Bond ETF
IEF
$47.1B
| $640K | 0.19% |
5,564
+5,284
| +1,887% | +$607K |
|
57
Merck
MRK
$324B
| $613K | 0.18% |
8,000
-1,750
| -18% | -$139K |
|
|
RWT
58
Redwood Trust
RWT
$616M
| $596K | 0.17% |
45,148
| – | – |
|
59
ClearPoint Neuro
CLPT
$423M
| $561K | 0.16% |
50,000
-7,500
| -13% | -$112K |
|
60
Sarepta Therapeutics
SRPT
$1.66B
| $540K | 0.16% |
6,000
-3,000
| -33% | -$256K |
|
61
ALX Oncology
ALXO
$273M
| $527K | 0.15% |
+24,500
| New | +$1.06M |
|
|
AMRN
62
Amarin Corp
AMRN
$284M
| $506K | 0.15% |
+7,500
| New | +$621K |
|
63
Fulcrum Therapeutics
FULC
$248M
| $504K | 0.15% |
+28,500
| New | +$565K |
|
64
MGIC Investment
MTG
$6.27B
| $487K | 0.14% |
33,775
| – | – |
|
|
SAGE
65
DELISTED
Sage Therapeutics
SAGE
| $468K | 0.14% |
11,000
+5,000
| +83% | +$209K |
|
66
iShares Russell 1000 Value ETF
IWD
$82B
| $423K | 0.12% |
+2,518
| New | +$413K |
|
67
Invesco S&P 500 Pure Value ETF
RPV
$1.61B
| $423K | 0.12% |
+5,237
| New | +$417K |
|
|
FUSN
68
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
| $417K | 0.12% |
100,000
+28,500
| +40% | +$178K |
|
69
Castle Biosciences
CSTL
$749M
| $407K | 0.12% |
+9,500
| New | +$496K |
|
70
iShares Russell 1000 Growth ETF
IWF
$122B
| $407K | 0.12% |
+5,328
| New | +$395K |
|
71
Invesco S&P 500 Pure Growth ETF
RPG
$2.04B
| $396K | 0.12% |
+9,400
| New | +$391K |
|
|
CMPS
72
Compass Pathways
CMPS
$1.52B
| $387K | 0.11% |
+17,500
| New | +$557K |
|
73
Iovance Biotherapeutics
IOVA
$2.23B
| $382K | 0.11% |
20,000
-10,500
| -34% | -$231K |
|
74
Agios Pharmaceuticals
AGIO
$2.16B
| $378K | 0.11% |
+11,500
| New | +$463K |
|
|
GTH
75
DELISTED
Genetron Holdings Limited ADS
GTH
| $375K | 0.11% |
+20,500
| New | +$679K |
|
Similar funds
AIS
IVGAI
OIM
TIP
RCG
CWM
SPW
WLC
AlphaCentric Advisors's Q4 2021 Portfolio in Review
As of Q4 2021, AlphaCentric Advisors held 286 positions worth $343M, down 13% from $393M the previous quarter. Its ten largest holdings account for 78% of the portfolio.
AlphaCentric Advisors withdrew a net $56.3M in Q4 2021, closing 66 positions and reducing 68 holdings. Its most notable exit was Vertex Pharmaceuticals, an estimated $1.86M position sold in full.
By sector, the portfolio is most concentrated in Real Estate at 24% of assets, up from 18% a quarter earlier, followed by Healthcare and Financials.
Against the trend, AlphaCentric Advisors opened a new position in Jazz Pharmaceuticals worth $1.27M.
- AlphaCentric Advisors's largest Q4 2021 buy was Jazz Pharmaceuticals: 10,000 shares worth $1.27M.
- AlphaCentric Advisors added most to iShares 1-3 Year Treasury Bond ETF in Q4 2021, an estimated $1.84M increase.
- AlphaCentric Advisors's biggest Q4 2021 reduction was Vanguard Mortgage-Backed Securities ETF, cutting an estimated $30.4M.
- AlphaCentric Advisors fully exited Vertex Pharmaceuticals in Q4 2021, selling an estimated $1.86M.
- AlphaCentric Advisors's ten largest holdings make up 78% of its $343M portfolio in Q4 2021.
- AlphaCentric Advisors opened 92 new positions and closed 66 in Q4 2021.
- AlphaCentric Advisors's portfolio value fell 13% quarter-over-quarter to $343M.
Based on AlphaCentric Advisors's 13F filing for Q4 2021, filed 25 Feb 2022.